10 Hartom Street, 2nd Floor
P.O. Box 45182
About Chiasma Inc.Chiasma is a biopharmaceutical company focused on improving the lives of patients who face challenges associated with existing treatments for their rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to select, develop and ultimately commercialize oral medications that are currently only available as injections.
Founders: Guy Yachin, Muli Ben Sasson
CEO: Mark Leuctenberger
CFO: Mark Fitzpatrick
Please click here for Chiasma job opportunitites.
Please click here for clinical trial information.
75 articles about Chiasma Inc.
Chiasma Inc. Appoints David Stack As Chairman Of The Board; John A. Scarlett, M.D. Joins Board Of Directors
Chiasma Inc. Release: Newly Published Phase 3 Study Results Show Positive Outcomes For Octreotide Capsules In People With Acromegaly, A Serious Hormonal Disorder
Chiasma Inc. Release: Data on Investigational Oral Octreolin™ for Acromegaly Demonstrate Growth Hormone Suppression
Chiasma (Israel) Ltd. Receives Orphan Drug Designation From the FDA for Octreolin(TM) for the Oral Treatment of Acromegaly